On the basis of improved overall survival, treatment guidelines strongly recommend
antifungal prophylaxis during remission induction chemotherapy for patients with acute …

Infectious complications are an important cause of morbidity and mortality in patients with
myelodysplastic syndromes (MDS). Preventing infections could significantly improve both …

Background Acute myeloid leukemia (AML) is a form of cancer that is characterized by
infiltration of the bone marrow, blood, and other tissues by proliferative, clonal, abnormally …

The number of newly diagnosed haematological malignancies in Polish adults and children
is about 9,000 a year, which constitutes about 5.5% of all malignancies in the country. Adult …

Simple Summary In patients with hematologic malignancies, especially those undergoing
intensive treatments like chemotherapy, infections pose a significant and life-threatening …

Simple Summary Azacitidine (AZA) is an essential drug in the treatment of myelodysplastic
syndromes (MDS) that has made it possible to extend patients' survival and improve their …

Background: The consequences of infectious toxicity of hypomethylating agents (HMAs) on
overall survival (OS) of patients diagnosed with high-risk myeloid neoplasms have not been …

The a priori risk for infections in patients with myelodysplastic syndromes (MDS) is unknown.
This study examines prescription rates of anti‐infective agents in MDS patients before and …

Background Azacitidine (AZA) is the standard of care for higher-risk myelodysplastic
syndrome (HR-MDS) patients ineligible for intensive therapy. Clinical outcome …

CMML is a heterogenous myelodysplastic/myeloproliferative neoplasm (MDS/MPN) sharing
both diseases' molecular and clinical phenotypes. Several models are used to risk-stratify …